Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Tamoxifen Dose Adjustment on ER+ Breast Cancer Patients Based on Genomic and Metabolite Concentrations Analysis

NCT04312347 is registered in ClinicalTrials.gov with Nalagenetics Pte Ltd as lead sponsor.

NCT NCT04312347
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04312347 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Tamoxifen Dose Adjustment on ER+ Breast Cancer Patients Based on Genomic and Metabolite Concentrations Analysis
Lead sponsor
Nalagenetics Pte Ltd
Phase
Not applicable
Overall status
Completed
Start date
September 6, 2019
Completion date
June 30, 2021
Enrollment
151 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

er+ breast cancer